Ophena ospemifene: Preliminary Phase III data

Preliminary results from a double-blind, placebo-controlled, U.S. Phase III trial showed that Ophena ospemifene met all 4 co-primary endpoints in a cohort of 314 patients who identified vaginal drynes...